Gilead Sciences Inc
NASDAQ: GILD
$89.88
+$0.74 (+0.8%)
Closing Price on January 10, 2025
GILD Articles
The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech stocks, short interest has decreased.
Published:
The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks.
Published:
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
Published:
There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend Monitor.
Published:
Back in November of 2010, 24/7 Wall St. first issued a list of stocks to own for the next decade. Even long-term investors need to assess their portfolios from time to time.
Published:
It turns out that hedge fund Bridgewater Associates and founder Ray Dalio have made some changes since the end of 2014.
Published:
The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks, short interest is down.
Published:
Gilead Sciences reported better than expected first-quarter results Thursday after the markets closed.
Published:
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. ThinkstockGilead Sciences Inc. (NASDAQ: GILD) will...
Published:
Last Updated:
The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Gilead Sciences is a major biotech involved with the EASL conference, and two analysts are calling heads and tails in terms of what the HCV news means for the stock.
Published:
In a new research note, Jefferies reviewed the 12-month change in revenue growth for the largest 30 companies in the S&P 500.
Published:
The March 13 short interest data in top biotechs have been compared with the end of February figures, and across the board all the selected stocks have seen their short interest increase.
Published:
Deutsche Bank says that investors have misread the current instances floating around two leading biotech stocks, and they both should be bought now on any continuing weakness.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.